| Dr Julie Kerri Miller, PHARMD | |
|
2080 S Queen St, York, PA 17403-4829 | |
| (717) 845-1633 | |
| Not Available |
| Full Name | Dr Julie Kerri Miller |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 2080 S Queen St, York, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104417898 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RP451777 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Julie Kerri Miller, PHARMD 60 Maple Run Dr, York, PA 17404-9124 Ph: () - | Dr Julie Kerri Miller, PHARMD 2080 S Queen St, York, PA 17403-4829 Ph: (717) 845-1633 |
News Archive
Researchers at the University of Cincinnati are helping to identify those most at risk in Ohio of overdosing on opiates.
Ambassador Eric Goosby, head of the U.S. State Department's Office of Global Health Diplomacy and the U.S. Global AIDS Coordinator, "is travelling to India this week to recognize the successful health partnership between the two countries, an official statement said," the Press Trust of India/Business Standard reports.
Schizophrenia is a chronic illness that most often comes on in late adolescence or young adulthood and can devastate patients' lives. Many physicians and researchers believe that early intervention can increase the chances for recovery, reduce recurrences and even prevent the warning signs of psychosis from progressing to the actual disease.
BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a clinical-stage rare disease and oncology company focused on sourcing and developing innovative treatments for underserved patient populations, announced today that the companies have entered into a global clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene's investigational RAF dimer inhibitor, lifirafenib and SpringWorks Therapeutics' investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors.
Canada's investments in drug information systems (DIS) will generate $436 million in cost savings and efficiencies in 2010, announced Richard Alvarez, President and CEO, Canada Health Infoway (Infoway). The findings are outlined in an independent study commissioned by Infoway, released today.
› Verified 3 days ago
Warren Daniels, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1861 Powder Mill Rd, York, PA 17402 Phone: 717-718-2000 | |
Caroline Alyce Dentler, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 25 Monument Rd Ste 265, York, PA 17403 Phone: 717-741-8150 | |
Mr. Daniel Allen Wright, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2350 E Market St, York, PA 17402 Phone: 717-840-3846 | |
Brandy Wright Quiles, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 304 Saint Charles Way, York, PA 17402 Phone: 717-851-5891 | |
Doris Ann Moore, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 W Market St, York, PA 17404 Phone: 717-854-6989 | |
Hayley Mcgee Murray, PHARMD RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3300 E Market St, York, PA 17402 Phone: 203-988-4643 | |
Mr. Robert Mark Santini, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 310 Harvest Field Ln, York, PA 17403 Phone: 717-848-2973 |